| 9th Jul 2019 12:00 pm |
GNW |
Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia |
| 20th Jun 2019 12:00 pm |
GNW |
Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 |
| 19th Jun 2019 12:00 pm |
GNW |
Result of AGM |
| 18th Jun 2019 12:00 pm |
GNW |
Increased BARDA Award and Option Exercise |
| 12th Jun 2019 12:00 pm |
GNW |
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 |
| 5th Jun 2019 2:00 pm |
GNW |
Notice of First Quarter Results |
| 14th May 2019 5:30 pm |
GNW |
UK Annual Report and Notice of AGM |
| 29th Apr 2019 12:30 pm |
GNW |
Block Listing Interim Review |
| 24th Apr 2019 4:20 pm |
GNW |
Exercise of Restricted Stock Units |
| 15th Apr 2019 7:00 am |
GNW |
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 |
| 3rd Apr 2019 12:00 pm |
GNW |
Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae |
| 2nd Apr 2019 12:00 pm |
GNW |
Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference |
| 29th Mar 2019 5:45 pm |
GNW |
Award of Share Options |
| 29th Mar 2019 11:15 am |
GNW |
Filing of Annual Report on Form 20-F |
| 27th Mar 2019 11:00 am |
GNW |
Final Results |
| 25th Mar 2019 11:00 am |
GNW |
Notice of Results |
| 18th Mar 2019 11:00 am |
GNW |
Summit Therapeutics to Present at Upcoming Conferences |
| 14th Mar 2019 11:00 am |
GNW |
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference |
| 25th Feb 2019 12:00 pm |
GNW |
Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data |
| 13th Feb 2019 12:00 pm |
GNW |
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection |
| 8th Feb 2019 12:00 pm |
GNW |
Summit Therapeutics to Present at the BIO CEO & Investor Conference |
| 15th Jan 2019 5:45 pm |
GNW |
Holding(s) in Company |
| 14th Jan 2019 12:00 pm |
GNW |
Award of Restricted Stock Units |
| 10th Jan 2019 4:15 pm |
GNW |
Holding(s) in Company |
| 10th Jan 2019 11:30 am |
GNW |
Holding(s) in Company |
| 10th Jan 2019 7:00 am |
GNW |
Completion of $25 million Subscription |
| 9th Jan 2019 4:45 pm |
GNW |
Holding(s) in Company |
| 8th Jan 2019 7:00 am |
GNW |
Update on Admission |
| 4th Jan 2019 12:30 pm |
GNW |
Result of General Meeting |
| 2nd Jan 2019 9:40 am |
GNW |
Holding(s) in Company |
| 18th Dec 2018 12:15 pm |
GNW |
Holding(s) in Company |
| 17th Dec 2018 7:05 am |
GNW |
Proposed Subscription to Raise $25m and Notice of General Meeting |
| 17th Dec 2018 7:00 am |
GNW |
Summit Therapeutics Announces Departure of Chief Financial Officer |
| 11th Dec 2018 12:00 pm |
GNW |
3rd Quarter Results |
| 6th Dec 2018 12:00 pm |
GNW |
Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018 |
| 30th Nov 2018 1:30 pm |
GNW |
Holding(s) in Company |
| 12th Nov 2018 12:00 pm |
GNW |
Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week |
| 12th Nov 2018 7:00 am |
GNW |
Appointment of Joint Broker |
| 7th Nov 2018 12:00 pm |
GNW |
Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference |
| 1st Nov 2018 4:34 pm |
GNW |
Holding(s) in Company |
